Hercules muscles in on IO space with AhR inhibtor

Armed with IP licensed exclusively from Boston University, the Dutch biotech Hercules Pharmaceuticals is targeting a receptor that is further down the validated pathway that IDO and TDO inhibitors are focused on. During BIO-Europe Spring 2018, Hercules CEO Bart Wuurman explained to Scrip how the company's lead AhR inhibiting candidate HP163, with an anticipated IND submission in early 2019, has the potential to treat solid tumors that do not respond to IDO inhibitors.